246 related articles for article (PubMed ID: 15693134)
1. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Tagliaferri P; Caraglia M; Budillon A; Marra M; Vitale G; Viscomi C; Masciari S; Tassone P; Abbruzzese A; Venuta S
Cancer Immunol Immunother; 2005 Jan; 54(1):1-10. PubMed ID: 15693134
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon and its effects on signalling pathways within cells.
Caraglia M; Vitale G; Marra M; Budillon A; Tagliaferri P; Abbruzzese A
Curr Protein Pept Sci; 2004 Dec; 5(6):475-85. PubMed ID: 15581417
[TBL] [Abstract][Full Text] [Related]
3. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.
Caraglia M; Marra M; Tagliaferri P; Lamberts SW; Zappavigna S; Misso G; Cavagnini F; Facchini G; Abbruzzese A; Hofland LJ; Vitale G
Curr Cancer Drug Targets; 2009 Aug; 9(5):690-704. PubMed ID: 19508175
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.
Murphy D; Detjen KM; Welzel M; Wiedenmann B; Rosewicz S
Hepatology; 2001 Feb; 33(2):346-56. PubMed ID: 11172336
[TBL] [Abstract][Full Text] [Related]
5. Antiapoptotic effect of interferon-alpha on hepatic stellate cells (HSC): a novel pathway of IFN-alpha signal transduction via Janus kinase 2 (JAK2) and caspase-8.
Saile B; Eisenbach C; El-Armouche H; Neubauer K; Ramadori G
Eur J Cell Biol; 2003 Jan; 82(1):31-41. PubMed ID: 12602946
[TBL] [Abstract][Full Text] [Related]
6. Alpha-interferon and its effects on signal transduction pathways.
Caraglia M; Marra M; Pelaia G; Maselli R; Caputi M; Marsico SA; Abbruzzese A
J Cell Physiol; 2005 Feb; 202(2):323-35. PubMed ID: 15389589
[TBL] [Abstract][Full Text] [Related]
7. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.
Arora T; Jelinek DF
J Biol Chem; 1998 May; 273(19):11799-805. PubMed ID: 9565604
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
9. Translational and post-translational modifications of proteins as a new mechanism of action of alpha-interferon: review article.
Caraglia M; Vitale G; Marra M; Del Prete S; Lentini A; Budillon A; Beninati S; Abbruzzese A
Amino Acids; 2004 Jul; 26(4):409-17. PubMed ID: 15290347
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
11. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
12. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.
Hobeika AC; Subramaniam PS; Johnson HM
Oncogene; 1997 Mar; 14(10):1165-70. PubMed ID: 9121765
[TBL] [Abstract][Full Text] [Related]
13. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
[TBL] [Abstract][Full Text] [Related]
14. Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.
Du Z; Fan M; Kim JG; Eckerle D; Lothstein L; Wei L; Pfeffer LM
J Biol Chem; 2009 Oct; 284(41):27808-27815. PubMed ID: 19687011
[TBL] [Abstract][Full Text] [Related]
15. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
Bukowski RM; Tendler C; Cutler D; Rose E; Laughlin MM; Statkevich P
Cancer; 2002 Jul; 95(2):389-96. PubMed ID: 12124839
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer.
Fujie H; Tanaka T; Tagawa M; Kaijun N; Watanabe M; Suzuki T; Nakayama K; Numasaki M
Cancer Sci; 2011 Nov; 102(11):1977-90. PubMed ID: 21883692
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha: regulatory effects on cell cycle and angiogenesis.
Rosewicz S; Detjen K; Scholz A; von Marschall Z
Neuroendocrinology; 2004; 80 Suppl 1():85-93. PubMed ID: 15477724
[TBL] [Abstract][Full Text] [Related]
18. How does interferon-alpha exert its antitumour activity in multiple myeloma?
Grandér D
Acta Oncol; 2000; 39(7):801-5. PubMed ID: 11145436
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.
Giandomenico V; Vaccari G; Fiorucci G; Percario Z; Vannuchi S; Matarrese P; Malorni W; Romeo G; Affabris GR
Eur Cytokine Netw; 1998 Dec; 9(4):619-31. PubMed ID: 9889406
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.
Eguchi H; Nagano H; Yamamoto H; Miyamoto A; Kondo M; Dono K; Nakamori S; Umeshita K; Sakon M; Monden M
Clin Cancer Res; 2000 Jul; 6(7):2881-90. PubMed ID: 10914738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
